Get in Touch

Orphan Drug Acquisition Advice

  • Access Strategy, Price Optimisation
P4A have given us credible and objective rationale that we’ve used to support decisions for acquisition of orphan therapies and devices.
Global Program Leader

Client Challenge

A complicated pipeline with many drugs in different stages of development and launch.

A large biotech were seeking to acquire a new asset and drug candidate. The biotech had ample resources but no coordination between in-house departments.

P4A Solution

P4A analysed the current situation: Opportunity assessment in short / medium term required.

Key areas of our assessment included:
  • Analog assessment
  • Price setting
  • Willingness to pay
  • Competitive environment

The Successful Outcome​

P4A obtained critical inputs for discussions with their commercial teams which included:

  • Better coordination among teams
  • Realistic negotiation position
  • Financially sound bid for target asset

Need more details?

Do you want to learn more about the successful outcome for this case study? Are you interested in P4A Services or just want to say Hi?

get in touch

Explore other case studies

Understand evidence requirements beyond clinical trial data for launching an orphan drug in Türkiye & the GCC

  • Access Strategy

Optimising the PRMA potential of an orphan oncology asset in EU4 + UK and Japan

  • Access Strategy, Price Optimisation
p4a-logo-small-retina-white

We are award winning global experts in access for orphan drugs and Cell and Gene Therapies.

Twitter Instagram Youtube Linkedin

About

Services

Insights

Case Studies

Contact

  • Aramislaan 88,
  • 6213BV Maastricht, Netherlands
  • +31 6 55 88 71 96
  • contact@partners4access.com

P4A Services

For all access and Rare Disease related overview enquiries